Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients

Edoardo Bruno Vicenzi, Elisabetta Calore, Nunzia Decembrino, Massimo Berger, Katia Perruccio, Francesca Carraro, Sara Rossin, Maria Caterina Putti, Mariadelfina Molinaro, Gloria Tridello, Simone Cesaro

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Posaconazole is a triazole with limited pharmacokinetic information in children. This study assessed the correlation between posaconazole oral solution daily dosage/kg/body weight and trough plasma level. Methods: A total of 97 hematology-oncology pediatric patients with ≥1 posaconazole plasma concentration level (PPC) assessment in the first 6 weeks after the start of posaconazole treatment were included. Results: Posaconazole was used as prophylaxis in 84 of 97 (87%) patients and as therapy in 13 of 97 (13%). The median daily dose/kg/bw ranged from 10 to 12 mg in the prophylaxis group and 12.5 to 16.5 mg in the therapy group. The median value of PPC for the prophylaxis group was 0.9 and 0.8 μg/mL at the first and second/third determinations, respectively. Posaconazole prophylaxis failed in 4 of 84 patients (5%). The median value of PPC for the therapy group was 1.5 and 1.4 μg/mL at the first/second and the third determination, respectively. Posaconazole-related side effects were reported in 6 patients and all regressed with the suspension of the drug. In the prophylaxis group, the use of proton-pump inhibitors was significantly associated with a lower PPC, P = 0.04. Conclusions: Posaconazole may be a valuable antifungal agent in children despite the incomplete knowledge of its pharmacokinetic characteristics.

Original languageEnglish
JournalEuropean Journal of Haematology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Hematology
Pediatrics
Group Psychotherapy
posaconazole
Pharmacokinetics
Triazoles
Proton Pump Inhibitors
Antifungal Agents
Suspensions
Body Weight

Keywords

  • Hematopoietic stem cell transplantation
  • Invasive fungal infection
  • Pediatric malignancy
  • Posaconazole
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Vicenzi, E. B., Calore, E., Decembrino, N., Berger, M., Perruccio, K., Carraro, F., ... Cesaro, S. (Accepted/In press). Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. European Journal of Haematology. https://doi.org/10.1111/ejh.13017

Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. / Vicenzi, Edoardo Bruno; Calore, Elisabetta; Decembrino, Nunzia; Berger, Massimo; Perruccio, Katia; Carraro, Francesca; Rossin, Sara; Putti, Maria Caterina; Molinaro, Mariadelfina; Tridello, Gloria; Cesaro, Simone.

In: European Journal of Haematology, 01.01.2018.

Research output: Contribution to journalArticle

Vicenzi, EB, Calore, E, Decembrino, N, Berger, M, Perruccio, K, Carraro, F, Rossin, S, Putti, MC, Molinaro, M, Tridello, G & Cesaro, S 2018, 'Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients', European Journal of Haematology. https://doi.org/10.1111/ejh.13017
Vicenzi, Edoardo Bruno ; Calore, Elisabetta ; Decembrino, Nunzia ; Berger, Massimo ; Perruccio, Katia ; Carraro, Francesca ; Rossin, Sara ; Putti, Maria Caterina ; Molinaro, Mariadelfina ; Tridello, Gloria ; Cesaro, Simone. / Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. In: European Journal of Haematology. 2018.
@article{7260aeb58c2744ff9d0eaa68556b6cf4,
title = "Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients",
abstract = "Background: Posaconazole is a triazole with limited pharmacokinetic information in children. This study assessed the correlation between posaconazole oral solution daily dosage/kg/body weight and trough plasma level. Methods: A total of 97 hematology-oncology pediatric patients with ≥1 posaconazole plasma concentration level (PPC) assessment in the first 6 weeks after the start of posaconazole treatment were included. Results: Posaconazole was used as prophylaxis in 84 of 97 (87{\%}) patients and as therapy in 13 of 97 (13{\%}). The median daily dose/kg/bw ranged from 10 to 12 mg in the prophylaxis group and 12.5 to 16.5 mg in the therapy group. The median value of PPC for the prophylaxis group was 0.9 and 0.8 μg/mL at the first and second/third determinations, respectively. Posaconazole prophylaxis failed in 4 of 84 patients (5{\%}). The median value of PPC for the therapy group was 1.5 and 1.4 μg/mL at the first/second and the third determination, respectively. Posaconazole-related side effects were reported in 6 patients and all regressed with the suspension of the drug. In the prophylaxis group, the use of proton-pump inhibitors was significantly associated with a lower PPC, P = 0.04. Conclusions: Posaconazole may be a valuable antifungal agent in children despite the incomplete knowledge of its pharmacokinetic characteristics.",
keywords = "Hematopoietic stem cell transplantation, Invasive fungal infection, Pediatric malignancy, Posaconazole, Prophylaxis, Treatment",
author = "Vicenzi, {Edoardo Bruno} and Elisabetta Calore and Nunzia Decembrino and Massimo Berger and Katia Perruccio and Francesca Carraro and Sara Rossin and Putti, {Maria Caterina} and Mariadelfina Molinaro and Gloria Tridello and Simone Cesaro",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ejh.13017",
language = "English",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients

AU - Vicenzi, Edoardo Bruno

AU - Calore, Elisabetta

AU - Decembrino, Nunzia

AU - Berger, Massimo

AU - Perruccio, Katia

AU - Carraro, Francesca

AU - Rossin, Sara

AU - Putti, Maria Caterina

AU - Molinaro, Mariadelfina

AU - Tridello, Gloria

AU - Cesaro, Simone

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Posaconazole is a triazole with limited pharmacokinetic information in children. This study assessed the correlation between posaconazole oral solution daily dosage/kg/body weight and trough plasma level. Methods: A total of 97 hematology-oncology pediatric patients with ≥1 posaconazole plasma concentration level (PPC) assessment in the first 6 weeks after the start of posaconazole treatment were included. Results: Posaconazole was used as prophylaxis in 84 of 97 (87%) patients and as therapy in 13 of 97 (13%). The median daily dose/kg/bw ranged from 10 to 12 mg in the prophylaxis group and 12.5 to 16.5 mg in the therapy group. The median value of PPC for the prophylaxis group was 0.9 and 0.8 μg/mL at the first and second/third determinations, respectively. Posaconazole prophylaxis failed in 4 of 84 patients (5%). The median value of PPC for the therapy group was 1.5 and 1.4 μg/mL at the first/second and the third determination, respectively. Posaconazole-related side effects were reported in 6 patients and all regressed with the suspension of the drug. In the prophylaxis group, the use of proton-pump inhibitors was significantly associated with a lower PPC, P = 0.04. Conclusions: Posaconazole may be a valuable antifungal agent in children despite the incomplete knowledge of its pharmacokinetic characteristics.

AB - Background: Posaconazole is a triazole with limited pharmacokinetic information in children. This study assessed the correlation between posaconazole oral solution daily dosage/kg/body weight and trough plasma level. Methods: A total of 97 hematology-oncology pediatric patients with ≥1 posaconazole plasma concentration level (PPC) assessment in the first 6 weeks after the start of posaconazole treatment were included. Results: Posaconazole was used as prophylaxis in 84 of 97 (87%) patients and as therapy in 13 of 97 (13%). The median daily dose/kg/bw ranged from 10 to 12 mg in the prophylaxis group and 12.5 to 16.5 mg in the therapy group. The median value of PPC for the prophylaxis group was 0.9 and 0.8 μg/mL at the first and second/third determinations, respectively. Posaconazole prophylaxis failed in 4 of 84 patients (5%). The median value of PPC for the therapy group was 1.5 and 1.4 μg/mL at the first/second and the third determination, respectively. Posaconazole-related side effects were reported in 6 patients and all regressed with the suspension of the drug. In the prophylaxis group, the use of proton-pump inhibitors was significantly associated with a lower PPC, P = 0.04. Conclusions: Posaconazole may be a valuable antifungal agent in children despite the incomplete knowledge of its pharmacokinetic characteristics.

KW - Hematopoietic stem cell transplantation

KW - Invasive fungal infection

KW - Pediatric malignancy

KW - Posaconazole

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85040333517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040333517&partnerID=8YFLogxK

U2 - 10.1111/ejh.13017

DO - 10.1111/ejh.13017

M3 - Article

AN - SCOPUS:85040333517

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -